This week, the International Contrast Ultrasound Society, which is a global organization that advocates for the safe and appropriate use of Contrast Enhanced Ultrasound (CEUS) to improve patient outcomes and experiences, highlights one of our paper: “High Frame-Rate Contrast Echocardiography: In-Human Demonstration“.
Ultrasound has been well established as a front line clinical imaging tool for diagnosis and treatment monitoring in a wide range of diseases such as cardiovascular diseases and cancer. Recently the development of novel microbubble contrast agents, together with other advances such as high frame-rate imaging technique, enables imaging and quantification of tissue structure and function with unprecedented sensitivity and resolution. Such techniques offer potentials to detect diseases and their responses to treatment at a much earlier stage and with greater accuracy.
Our group are working on the development of new imaging techniques using ultrasound and allied technologies (contrast agents, photoacoustics), together with signal processing, to better visualise and quantify blood flow, perfusion, molecular targets and tissue elasticity properties, and their clinical applications in the diagnosis and treatment of cardiovascular diseases, cancer and neurological conditions.